Replies to post #243 on Equity Field Notes from temporal sources

[DanWebzster]

ISR the worldwide market for Cesium-131 radiation therapies is gradually improving and this company has cornered it.

Presently, the great majority of revs come from selling brachytherapy seeds for prostrate cancer patients.

This week, FDA approved their collagen-based Cesium-131 carrier technology for recurrent brain tumors.

In the most recent Q, revs were up 23% YOY.

With this financing, cash runway now extends into 2020.

The next time this stock bases, it will likely be a good investment.